http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H01106819-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef2e9f5ce8630d9b282043b8d060caff |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-557 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 |
| filingDate | 1988-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27167fd422a72d331af1c834703ec219 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_614b30e5af6e73441adb8e3e19cf621b |
| publicationDate | 1989-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H01106819-A |
| titleOfInvention | Pupil contraction and intraocular pressure decreasing agent |
| abstract | PURPOSE: To obtain a pupil contraction and intraocular pressure decreasing agent that contains thromboxane B2 as an effective ingredient, contracts the pupil, decreases the intraocular pressure, especially is suitable for intraocular operation, for example, to contracts the pupil after transplantation of a crystalline lens, and useful for maintaining the crystalline lens after the operation at a correct position. CONSTITUTION: This pupil contraction and intraocular pressure decreasing agent comprises thromboxane B2 as an effective ingredient to be used in the form of a solution, suspension, gel, or ointment for ophthalmic treatment. Thromboxane B2, which is a substance synthesized in the intestine and lung, kidney and eye tissues by platelets and blood vessels, can contract the pupil when administered in a quantity of approximately 50-500ng to the eye for operation, preferably at a time near the end of operation. When administered after the wound is closed, or when applied to an unwounded eye, it is preferably used in a quantity of approximately 1μg-100mg as the effective ingredient. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017078089-A |
| priorityDate | 1987-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.